AVBP · ArriVent BioPharma, Inc.
$28.26
+0.04 (+0.14%)
At close · Jul 21
Market Cap
$1.32B
Shares
46.57M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$166.31M
-106.6%
FY2025
Diluted EPS
-$4.32
-68.8%
FY2025
Operating Cash Flow
-$160.59M
-128.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $129.68M | $153.35M | $79M | |
| $27.19M | $24.18M | $15.3M | |
| — | -$3.03M | — | |
| $156.87M | $177.53M | $94.31M | |
| -$156.87M | -$177.53M | -$94.31M | |
| -$145.24M | -$166.31M | -$80.49M | |
| -$145.49M | -$166.08M | -$80.7M | |
| USD/shares | — | -$4.32 | -$2.56 |
| USD/shares | — | -$4.32 | -$2.56 |
| shares | — | 38.46M | 31.47M |
| shares | — | 38.46M | 31.47M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Key facts
CIK
1868279
CUSIP
04272N102
13F (30d)
11 filings
11 filers
Visit website
Investor relations